Search

We report on a 43-year-old male who sustained an isolated distraction injury of the thoracic spine Th7/Th8 (AO/ASIF B 2.3) with wedge compression Th8 and sagittal split Th10 without neurological injury. A bisegmental posterior stabilisation and a monosegmental interlaminar fusion was the treatment of choice. A synthetic bone substitute, beta-tricalcium phosphate (beta-TCP, Chronos) without additional autogenous bone was used to achieve the monosegmental posterior fusion. The clinical course was favourable and 10 months postoperatively the implant was removed. On implant removal the CT scan showed a fused segment and intraoperatively it was found that the fusion was solidly healed. A biopsy was taken from the fusion mass and histology showed vital bone that was rich with osteocytes. Noncalcified osteoid surrounding the bone marrow cavity could be identified. Several studies and the reported case might indicate that osteoconductive material alone can be sufficient for achieving a solid fusion. [ABSTRACT FROM AUTHOR]

Summary: In the present study, we evaluated the potential for aminobisphosphonates to enhance the development of bone-forming osteoblasts from progenitor cells isolated from aged female osteoporotic patients. The aminobisphosphonates tested significantly enhanced osteoblast formation and thus lend further insights into their possible mode of action in the treatment of osteoporosis. Introduction: The primary aim of this study was to evaluate the influence of aminobisphosphonates on the osteogenesis of human bone marrow stromal cells (hBMSCs) and mineralization of differentiating bone-forming cells isolated from osteoporotic patients. Methods: The influence of aminobisphosphonate treatment on hBMSC osteogenesis was assessed by the quantitative measurement of alkaline phosphatase (ALP) activity, in addition to quantitative reverse transcription polymerase chain reaction and Western blot analysis of known osteogenic markers. Mineralized matrix formation by hBMSC-derived osteoblasts was visualized and quantified using Alizarin red staining. Results: hBMSC cultures treated with osteogenic medium supplemented with zoledronate demonstrated a significant increase in Alizarin red staining after 3 weeks as compared to cells cultured in osteogenic medium alone. Similarly, cultures of differentiating hBMSCs isolated from patients receiving alendronate treatment also demonstrated an increased propensity for mineralization, even in the absence of further in vitro stimulation by zoledronate. The stimulatory effects of aminobisphosphonate treatment on hBMSC-derived osteoblast-mediated mineralization were independent of any alterations in ALP activity, although significant decreases in the expression levels of osteopontin ( SPP1) were evident in hBMSCs following exposure to aminobisphosphonates. Further analysis including Western blotting and loss-of-function studies revealed osteopontin as having a negative influence on the mineralization of differentiating osteoporotic bone-forming cells. Conclusions: The results presented here demonstrate for the first time that aminobisphosphonate treatment of osteoporotic hBMSCs enhances their capacity for osteoblast formation and subsequent mineral deposition, thus supporting the concept of aminobisphosphonates as having an osteoanabolic effect in osteoporosis. [ABSTRACT FROM AUTHOR]